CN1638775A - 治疗疾病和损伤用的氧化氮供体 - Google Patents

治疗疾病和损伤用的氧化氮供体 Download PDF

Info

Publication number
CN1638775A
CN1638775A CNA038048817A CN03804881A CN1638775A CN 1638775 A CN1638775 A CN 1638775A CN A038048817 A CNA038048817 A CN A038048817A CN 03804881 A CN03804881 A CN 03804881A CN 1638775 A CN1638775 A CN 1638775A
Authority
CN
China
Prior art keywords
cells
rats
sildenafil
brain
neurogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038048817A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·乔普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Original Assignee
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System filed Critical Henry Ford Health System
Publication of CN1638775A publication Critical patent/CN1638775A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA038048817A 2002-01-04 2003-01-06 治疗疾病和损伤用的氧化氮供体 Pending CN1638775A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34547802P 2002-01-04 2002-01-04
US60/345,478 2002-01-04

Publications (1)

Publication Number Publication Date
CN1638775A true CN1638775A (zh) 2005-07-13

Family

ID=23355218

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038048817A Pending CN1638775A (zh) 2002-01-04 2003-01-06 治疗疾病和损伤用的氧化氮供体

Country Status (9)

Country Link
US (2) US20050143388A1 (enExample)
EP (1) EP1469852A4 (enExample)
JP (2) JP4545440B2 (enExample)
CN (1) CN1638775A (enExample)
AU (1) AU2003210447B2 (enExample)
CA (1) CA2471147C (enExample)
IL (1) IL162850A0 (enExample)
WO (1) WO2003056899A2 (enExample)
ZA (1) ZA200405507B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
EP1951237A2 (en) * 2005-11-14 2008-08-06 The Trustees of Columbia University in The City of New York Imaging correlates of neurogenesis with mri
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
JP2010527928A (ja) 2007-05-18 2010-08-19 ヴィヴァス・インコーポレイテッド ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
WO2009059271A1 (en) * 2007-11-02 2009-05-07 University Of Miami Diagnosis and treatment of cardiac disorders
MY173949A (en) 2012-04-25 2020-02-28 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
CA2908482A1 (en) * 2013-03-01 2014-09-04 Fundacion Para La Investigacion Medica Aplicada Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
US10297661B2 (en) * 2017-06-30 2019-05-21 Taiwan Semiconductor Manufacturing Co., Ltd. High voltage resistor device
US20250041309A1 (en) * 2021-12-14 2025-02-06 Zhenao Jinyinhua Pharmaceutical Use of aildenafil or salt thereof in preparation of medicine for preventing or treating ischemic brain damage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755685A4 (en) * 1994-04-15 2000-05-03 Meiji Seika Kaisha PHARMACEUTICAL COMPOSITION FOR TREATING LATE DYSKINESIA
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
ES2531592T3 (es) 1999-05-14 2015-03-17 Henry Ford Health System Trasplante de médula ósea para el tratamiento de la apoplejía
IL147112A0 (en) 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
US6271228B1 (en) 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
EP2316531A1 (en) * 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Augmented cognitive training

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Also Published As

Publication number Publication date
CA2471147A1 (en) 2003-07-17
JP2005514406A (ja) 2005-05-19
JP4545440B2 (ja) 2010-09-15
US20120009152A1 (en) 2012-01-12
CA2471147C (en) 2010-08-10
ZA200405507B (en) 2005-05-25
IL162850A0 (en) 2005-11-20
US20050143388A1 (en) 2005-06-30
EP1469852A2 (en) 2004-10-27
WO2003056899A9 (en) 2004-04-15
WO2003056899A3 (en) 2003-11-27
AU2003210447B2 (en) 2008-02-07
AU2003210447A1 (en) 2003-07-24
EP1469852A4 (en) 2009-12-02
WO2003056899A2 (en) 2003-07-17
JP2009256374A (ja) 2009-11-05

Similar Documents

Publication Publication Date Title
US20120009152A1 (en) Nitric oxide donors for treatment of disease and injury
CN1615143A (zh) 来自骨髓基质细胞的用于形成血管并产生血管生成和营养因子的物质
CN1177831C (zh) 作为离子通道调节剂的新的苯并咪唑啉酮一、苯并噁唑酮一或苯并噻唑啉酮衍生物
US20170000779A1 (en) Modulation of Stem Cell and Progenitor Cell Differentiation, Assays, And Uses Thereof
CN1589330A (zh) 胰岛干细胞及其在治疗糖尿病中的用途
CN1543500A (zh) 从人多能干细胞产生心肌细胞系细胞
JP2021531288A (ja) 眼疾患のミトコンドリア増強療法
CN1681918A (zh) 单核细胞起源的移植物接纳诱导性细胞及其制备和用途
JP2021532093A (ja) 脳疾患のミトコンドリア増強療法
JP2021532094A (ja) 筋疾患のミトコンドリア増強療法
JP2021532095A (ja) 肝臓疾患のミトコンドリア増強療法
JP2023519744A (ja) ミトコンドリア増強療法
US10751368B2 (en) Methods of transplantation and disease treatment
CN1671836A (zh) 用于基因治疗的原代培养脂肪细胞
CN101068570A (zh) 双嘧达莫治疗血小板抑制剂的抗药性的用途
US20080279866A1 (en) Induction of immunosuppression by inhibition of ATM
JP2026506930A (ja) パーキンソン病、並びに他の一次性及び二次性パーキンソニアン障害を処置するための組合せ
US20190167674A1 (en) Vigor enhancement via administration of pyrimidine derivatives
CN1638791A (zh) 包含红细胞生成素的稳定的药物组合物
CN1655818A (zh) 非肽类ccr1受体拮抗剂联合环孢菌素a治疗心脏移植排异反应
CN1668333A (zh) 包含红细胞生成素的稳定的药物组合物
CN1310672C (zh) 作为造血刺激物的成骨生长寡肽
JP2022505615A (ja) 造血幹・前駆細胞移植療法の方法
Corpuz Role of Macrophages in Ocular Surface Fibrosis
JP2024537531A (ja) 拡大培養したイヌ前駆細胞および関連する方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication